Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression.

If a mathematical model is to be used in the diagnosis, treatment, or prognosis of a disease, it must describe the inherent quantitative dynamics of the state. An ideal candidate disease is prostate cancer owing to the fact that it is characterized by an excellent biomarker, prostate-specific antigen (PSA), and also by a predictable response to treatment in the form of androgen suppression therapy. Despite a high initial response rate, the cancer will often relapse to a state of androgen independence which no longer responds to manipulations of the hormonal environment. In this paper, we present relevant background information and a quantitative mathematical model that potentially can be used in the optimal management of patients to cope with biochemical relapse as indicated by a rising PSA.

[1]  E. Trucco,et al.  [HORMONES AND CANCER]. , 1964, La Semana medica.

[2]  References , 1971 .

[3]  L. Klotz,et al.  Intermittent endocrine therapy for advanced prostate cancer , 1986, Cancer.

[4]  Richard P. Hill,et al.  The Basic Science of Oncology , 1989 .

[5]  S. Goldenberg,et al.  Effects of intermittent androgen suppression on androgen‐dependent tumors. Apoptosis and serum prostate‐specific antigen , 1993, Cancer.

[6]  U. Tunn.  Intermittent endocrine therapy of prostate cancer. , 1996, European urology.

[7]  N. Hay,et al.  Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. , 1998, Molecular endocrinology.

[8]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[9]  C. Huggins,et al.  Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. , 2002, The Journal of urology.

[10]  Daniel Liberzon,et al.  Switching in Systems and Control , 2003, Systems & Control: Foundations & Applications.

[11]  Thomas L. Jackson,et al.  A mathematical model of prostate tumor growth and androgen-independent relapse , 2003 .

[12]  Trachette L. Jackson,et al.  A mathematical investigation of the multiple pathways to recurrent prostate cancer: comparison with experimental data. , 2004, Neoplasia.

[13]  C. Tangen,et al.  Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. , 2004, Urology.

[14]  Chih-Pin Chuu,et al.  Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. , 2005, Cancer research.

[15]  Stephen Hsu,et al.  Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity , 2005, The Prostate.

[16]  Nicholas Bruchovsky,et al.  Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer , 2006, Cancer.

[17]  Nicholas Bruchovsky,et al.  Locally advanced prostate cancer—biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate‐specific antigen recurrence after radiotherapy , 2007, Cancer.

[18]  Gouhei Tanaka,et al.  A Mathematical Model of Intermittent Androgen Suppression for Prostate Cancer , 2008, J. Nonlinear Sci..

[19]  Gouhei Tanaka,et al.  Bifurcation analysis on a hybrid systems model of intermittent hormonal therapy for prostate cancer , 2008 .

[20]  N. Bruchovsky,et al.  Quality of Life, Morbidity, and Mortality Results of a Prospective Phase II Study of Intermittent Androgen Suppression for Men with Evidence of Prostate-Specific Antigen Relapse After Radiation Therapy for Locally Advanced Prostate Cancer , 2008 .

[21]  Kazuyuki Aihara,et al.  Mathematical Modeling of Prostate Tumor Growth under Intermittent androgen Suppression with Partial Differential Equations , 2008, Int. J. Bifurc. Chaos.

[22]  Kazuyuki Aihara,et al.  A nonlinear model with competition between prostate tumor cells and its application to intermittent androgen suppression therapy of prostate cancer. , 2008, Mathematical biosciences.

[23]  C. Takimoto,et al.  Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes , 2009, Clinical Cancer Research.

[24]  Kazuyuki Aihara,et al.  A MODEL AT THE MACROSCOPIC SCALE OF PROSTATE TUMOR GROWTH UNDER INTERMITTENT ANDROGEN SUPPRESSION , 2009 .

[25]  R. Vessella,et al.  Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.

[26]  C. Klein,et al.  Parallel progression of primary tumours and metastases , 2009, Nature Reviews Cancer.

[27]  Hideyuki Suzuki,et al.  Theory of hybrid dynamical systems and its applications to biological and medical systems , 2010, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[28]  Kazuyuki Aihara,et al.  Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer. , 2010, Journal of theoretical biology.

[29]  Kazuyuki Aihara,et al.  Piecewise affine systems modelling for optimizing hormone therapy of prostate cancer , 2010, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[30]  Kazuyuki Aihara,et al.  Hybrid optimal scheduling for intermittent androgen suppression of prostate cancer. , 2010, Chaos.

[31]  Kazuyuki Aihara,et al.  A Mathematical Model of Prostate Tumor Growth Under Hormone Therapy with Mutation Inhibitor , 2010, J. Nonlinear Sci..

[32]  Guy Dimonte,et al.  A cell kinetics model for prostate cancer and its application to clinical data and individual patients. , 2010, Journal of theoretical biology.

[33]  Donatello Telesca,et al.  Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Yuri Kogan,et al.  Predicting Outcomes of Prostate Cancer Immunotherapy by Personalized Mathematical Models , 2010, PloS one.

[35]  Yang Kuang,et al.  The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model , 2010, Biology Direct.

[36]  Gouhei Tanaka,et al.  Mathematical modelling of prostate cancer growth and its application to hormone therapy , 2011, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[37]  Kazuyuki Aihara,et al.  Nonlinear systems identification by combining regression with bootstrap resampling. , 2011, Chaos.

[38]  Avner Friedman,et al.  Mathematical modeling of prostate cancer progression in response to androgen ablation therapy , 2011, Proceedings of the National Academy of Sciences.

[39]  Gouhei Tanaka,et al.  Mathematically modelling and controlling prostate cancer under intermittent hormone therapy. , 2012, Asian journal of andrology.

[40]  Travis Portz,et al.  A clinical data validated mathematical model of prostate cancer growth under intermittent androgen suppression therapy , 2012 .

[41]  Toshiyuki Yamamoto,et al.  CONFLICT OF INTEREST: None declared. , 2013 .